Study designed by medical oncologist to accelerate lifesaving care to patients
“Colorectal cancer is the second deadliest cancer in the
This year alone, an estimated 159,000 Americans will be diagnosed with colorectal cancer, and the disease will claim about 55,230 lives, according to the
“Based on insights gleaned from past studies, we expect this powerful drug combination will result in more potent activation of the immune system within tumors, leading to potential tumor regression or death,”
Physician-led innovation to reshape patient care
Investigator-initiated trials like this one are clinical studies designed by doctors or scientists rather than an industry sponsor. Fueled by researchers’ scientific curiosity, medical insight and dedication to patient-centered care, these trials provide independent, real-world data that can ignite therapeutic advances and shift clinical guidelines.
“We hope that the combination of immunotherapy with ivonescimab and ADG126 will work hand in hand with chemotherapy to improve further tumor shrinkage in advanced colorectal cancer,”
“ADG126 is designed to activate preferentially in the tumor microenvironment, enabling CTLA-4 blockade while limiting on-target, off-tumor activity in healthy tissues. By combining this approach with complementary immune, angiogenic and cytotoxic mechanisms, the study will assess the safety and preliminary antitumor activity of these regimens. We value City of Hope’s leadership and clinical expertise in colorectal cancer.”
Fighting a high risk of recurrence
Some 85% of colorectal cancer cases are classified as microsatellite stable (MSS), which has a higher risk of returning after treatment. Despite numerous clinical studies, no new therapies have outperformed existing treatments in halting growth.
Recent findings, however, have suggested promising new directions, including:
- Integrating ivonescimab and chemotherapy significantly improved results in a small trial of 22 people, with 82% of the patients responding positively.
- Blending two treatments — one targeting a protein called PD-1 and another targeting blood vessel growth (VEGFR) — helped patients whose colorectal cancer had not spread to the liver.
- Ivonescimab targets both PD-1 and VEGF, potentially enhancing effectiveness while reducing side effects. When paired with drugs that block PD-1, ADG126 boosted the immune system’s ability to combat cancer.
Building off these discoveries,
In integrating the approach with traditional chemotherapy, his work aims to pinpoint the safest dosage for new drug combinations and determine how long they combat cancer growth.
“The clock is ticking; we can’t afford to lose more patients to this devastating disease,”
*
About
Powered by its proprietary
Adagene’s lead clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 on regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently being evaluated in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly in microsatellite stable (MSS) metastatic colorectal cancer (CRC). The
For more information, please visit: https://investor.adagene.com.
Follow
SAFEbody® is a registered trademark in
About City of Hope
City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked among the nation’s top cancer centers by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, Orange County, California, campus, a network of clinical care locations across Southern California and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding the initiation, timing, conduct and completion of the investigator-initiated Phase 1 study of muzastotug in combination with ivonescimab, with or without chemotherapy; the potential safety, tolerability, pharmacokinetic profile and antitumor activity of the investigational regimens; the identification of recommended Phase 2 doses; and Adagene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of, its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by relevant regulatory authorities regarding approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations; and those risks more fully discussed in the “Risk Factors” section of Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor Contacts:
Raymond Tam
Raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

